M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
M V Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared a post on LinkedIn:
“Aspirin in CRC – Old Drug, New Precision Oncology?
ALASCCA | 4-part quick revision
Part 1 – Why Aspirin?
The biology: PI3K–COX/PGE2 signaling and platelet-mediated metastatic escape as proposed mechanisms.
Part 2 – Who Got Aspirin?
Resected localized CRC and PI3K-pathway alteration – aspirin 160 mg/day vs placebo × 3 years.
Part 3 – Did it Work?
Primary Group A: 3-year recurrence 14.1% – 7.7% | HR 0.49.
Benefit also seen in the broader PI3K-altered Group B; absolute benefit was greater in higher-risk disease.
Part 4 – What Does It Men?
A compelling example of biomarker-directed drug repurposing – but OS benefit is not yet proven, and subgroup signals require caution.
Take-home:
Not aspirin for every CRC – aspirin for the right biology.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines